Deerfield Management

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6606001

SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the third quarter ended September 30, 2009. Arena reported a lower net loss allocable to common stockholders in the third quarter of 2009 of $34.8 million, or $0.38 per share, compared to a net loss allocable to common stockholders in the third quarter of 2008 of $56.2 million, or $0.76 per share, and a net loss allocable to common stockholders in the first nine months of 2009 of $123.4 million, or $1.51 per share, compared to a net loss allocable to common stockholders in the first nine months of 2008 of $177.0 million, or $2.40 per share. "The successful completion of the lorcaserin pivotal program in the third quarter was a critical milestone for Arena," stated Jack Lief, Arena's President and Chief Executive Officer. "The positive results were received with support and enthusiasm at The ...

Increased revenues and reduced expenses drive substantial improvement in quarterly net loss RECOTHROM sales increase to $8.5 million compared to $1.8 million a year earlier SEATTLE--(BUSINESS WIRE)-- ZymoGenetics, Inc. (NASDAQ: ZGEN) today reported improved financial results for the third quarter ended September 30, 2009. The company's net loss for the quarter declined substantially to $11.4 million, or $0.17 per share, from $28.8 million, or $0.42 per share, for the third quarter of 2008. Revenues for the third ...

BEDFORD, MA -- (MARKET WIRE) -- 10/26/09 -- Insulet Corporation (NASDAQ: PODD), the leader in tubing-free insulin pump technology with its OmniPod® Insulin Management System, today announced financial results for the three and nine months ended September 30, 2009. Third quarter 2009 revenue increased 85% to $18.7 million, compared to $10.1 million in the third quarter of 2008. On a sequential basis, revenue increased 28% from $14.6 million in the second quarter of 2009. Gross profit for the third quarter of 2009 was $5.8 million, representing a 31% gross margin, compared to a gross loss of $0.1 million, or a (1%) gross margin, for the third quarter of 2008. On a sequential basis, gross profit increased 83% from $3.2 million in the second quarter of 2009. Operating loss for the third quarter of 2009 was $13.5 million, a 32% improvement compared to operating loss of $19.8 million in the third quarter of 2008. Total operating expenses were $19.3 ...

WASHINGTON--(BUSINESS WIRE)-- The Biotechnology Industry Organization (BIO) today announced Plenary Session and Business Roundtable topics for the Eighth Annual BIO Investor Forum, taking place October 28-29 at the Palace Hotel in San Francisco, Calif. The conference will feature sessions addressing current investment and financing trends in the biotechnology industry and more than 100 presentations by selected late-stage private and emerging public companies. "We are coming out of a period of intense pressure and conservatism in life sciences investment, while in the midst of an extraordinary policy debate on ...